Test Price
2,800 AED✅ Home Collection Available
GABRG2 Gene Dravet Syndrome Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Diagnostic Precision: 99.9% Diagnostic Sensitivity via ISO 15189 & ISO 9001:2015 Accredited Next‑Generation Sequencing (NGS) Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection, available daily from 8 AM to 11 PM.
Clinical Guidance: Post‑Test Clinical Interpretation by Consultant Medical Genetics Lina Osama Zaki Quteineh (DHA Registration ID: 9294403).
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The GABRG2 Gene Dravet Syndrome Genetic Test provides comprehensive sequencing of the gamma‑aminobutyric acid type A receptor subunit gamma2 gene, identifying pathogenic or likely pathogenic variants that confirm a diagnosis of Dravet syndrome (severe myoclonic epilepsy of infancy). This molecular analysis is the gold standard for confirming the genetic aetiology of treatment‑resistant epilepsy and guiding personalised anti‑epileptic strategies in the UAE.
| Parameter | Our Test (ISO 15189 & ISO 9001:2015) | Closest Alternative |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) with full gene coverage, CNV detection and variant classification per ACMG guidelines | Sanger sequencing of select exons (limited sensitivity) |
| Sample Type | Whole Blood (1–4 mL EDTA), Extracted DNA, or Dry Blood Spot on FTA Card | Whole Blood (larger volumes often required) |
| Turnaround Time | 3 to 4 Weeks | 5 to 8 Weeks |
| Specialist Review | Consultant Medical Genetics interpretation included | Laboratory report only |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialising in neurodevelopmental disorders, I emphasise that comprehensive GABRG2 sequencing must be paired with detailed clinical phenotyping. A positive result provides definitive molecular confirmation of Dravet syndrome, but management decisions must always integrate seizure semiology, developmental trajectory, and tailored pharmacotherapy.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Medication Advisory
Medication Warning
Do not discontinue any prescribed anti‑epileptic drugs or other medications without prior consultation with your treating physician. Abrupt withdrawal can precipitate life‑threatening status epilepticus. Please inform the phlebotomist about any blood‑thinning medications prior to sample collection.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Active febrile illness requiring hospitalisation; known coagulopathy preventing venipuncture; inability to provide informed consent (per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Emergency: If the patient experiences a prolonged seizure lasting more than 5 minutes, febrile status epilepticus, or significant motor decline after sampling, seek immediate emergency medical care rather than awaiting the genetic result.
- Informed Consent: A genetic counselling session is mandatory prior to testing to draw a pedigree chart of affected family members and obtain written informed consent in compliance with UAE federal health regulations.
Patient FAQ & Clinical Guidance
1. What is Dravet syndrome and how does this NGS test confirm it?
Dravet syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a rare genetic epilepsy syndrome characterised by prolonged febrile and afebrile seizures beginning in the first year of life. This NGS test detects pathogenic or likely pathogenic variants in the GABRG2 gene with 99.9% sensitivity, providing definitive molecular confirmation of the diagnosis (ICD-10-CM: G40.834) and guiding personalised anti‑epileptic treatment strategies.
2. What is the turnaround time for the GABRG2 genetic test and what sample types are accepted?
The final clinical report is issued within 3 to 4 weeks of sample receipt. Acceptable specimen matrices include whole blood collected in EDTA tubes (1–4 mL), extracted DNA of sufficient quality and quantity, or a dry blood spot collected on an FTA card. Our VIP Mobile Phlebotomy service can collect the sample from your home between 8 AM and 11 PM daily.
3. What pre‑test steps are required before the blood draw?
A mandatory genetic counselling session is conducted to draw a pedigree chart of affected family members and to obtain written informed consent. No fasting is required for this test. Please inform our phlebotomist about any blood‑thinning medications or anticoagulant therapy prior to collection.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Governance
All genetic and personal data are processed and stored in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety, patient consent, and medical liability are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE adheres to the highest standards of confidentiality and data security for all diagnostic and clinical genomic information.
Clinical & Logistical Metadata
| Test Name | GABRG2 Gene Dravet Syndrome Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (1–4 mL EDTA), Extracted DNA, or Dry Blood Spot on FTA Card |
| Methodology Used | Next‑Generation Sequencing (NGS) with CNV Detection |
| ICD-10-CM Code | G40.834 |
| LOINC Code | 101186-7 |
| DHA Facility License & Laboratory Address | DHA License Number 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians